Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT01619332
- Study
- In this atlas
Overview
- Design
- Interventional study; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 220 participants
- Sponsor
- Registry
-
NCT01619332
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01619332. Quadruple masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2013-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
- Condition
- Type II Diabetes
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- LEZ763
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01619332- Content hash
6c1da4f5f2280d300ad985f0063ed27e38d908a68b75d16b986dd4bf3906dd2d